Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
15.9.2021 11:00:00 EEST | Business Wire | Press release
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.
“While precision oncology has made a meaningful difference in improving clinical outcomes for highly prevalent cancers, such as non-small cell lung, colorectal, and breast, there remains a subset of patients who don’t respond to currently available treatments,” said Craig Eagle, MD, Guardant Health Chief Medical Officer. “It is gratifying to be able to work with the oncology community to analyze the molecular information generated from our liquid biopsy tests to continue to increase our understanding of possible new targets and more personalized treatments which can potentially improve overall survival of these hard-to-treat cancers in a more meaningful way.”
Guardant INFORM™ Liquid Biopsy Dataset Shows No Clear Standard of Care and Unmet Need for Patients with HER2+ Metastatic Colorectal Cancer
|
Title |
ePoster |
Presenter |
|
Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study |
439P |
John Strickler |
Guardant360® Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer
|
Title |
ePoster |
Presenter |
|
Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO) |
500P |
Julia Alcaide-Garcia |
|
Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR) |
503P |
Manuel Benavides |
Guardant360® Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic
|
Title |
ePoster |
Presenter |
|
First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA) |
92P |
Javier Garcia-Corbacho |
|
Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) |
1196P |
Ben J. Solomon |
|
Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer |
1483P |
Pedro Uson Junior |
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005307/en/
Contact information
Investor Contact:
Carrie Mendivil
investors@guardanthealth.com
Media Contact:
Anna Czene
press@guardanthealth.com
Julie Johnson
julie.johnson@uncappedcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Torq Becomes the Cursor of Security Operations With New Agentic Builder18.3.2026 16:47:00 EET | Press release
Torq, the established agentic security operations leader, today unveiled Agentic Builder, a critical extension of the Torq AI SOC Platform that turns human intent into agentic outcomes. Agentic Builder enables SOCs to shift the cognitive load of engineering security automation from humans to machines. These Cursor-level capabilities eliminate all barriers to deliver production-grade agentic workflows and AI Agents that manage unlimited alerts 24x7, integrate with every level of the enterprise stack, streamline investigation, and respond at machine speed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318328878/en/ This news follows Torq’s recent announcement that it has secured a $140M Series D round at $1.2B valuation to lead the AI SOC and Agentic AI era. Torq AI Agents are now deeply embedded in the daily operations of Fortune 500 SOCs, managing millions of complex security tasks autonomously. Torq now protects hundred
Laserfiche Announces 2026 Run Smarter® Award Winners18.3.2026 16:17:00 EET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — today announced the winners of the 2026 Laserfiche Run Smarter® Awards. These awards celebrate the visionaries and trailblazers who are redefining the possible, using Laserfiche to break down operational silos and catalyze a new era of enterprise-wide productivity. From a large city reimagining criminal justice to a financial services firm’s innovative use of AI for smarter service delivery: The winners enhance productivity, reimagine processes and improve lives with Laserfiche technology. “The true power of Laserfiche has always been in how it unlocks value — whether that is through delivering actionable intelligence, cost savings, or reclaimed time to put toward innovation,” said Karl Chan, CEO of Laserfiche. “This year’s honorees are at the forefront of information management, with many of them leveraging cloud and AI technology to modernize processes and achieve business transformation.” Congratulations to t
Andersen Consulting Bolsters Cybersecurity Offering Through Collaboration with Trillium Information Security Systems18.3.2026 15:30:00 EET | Press release
Andersen Consulting strengthens its technology and risk management capabilities through a Collaboration Agreement with Trillium Information Security Systems (TISS), a cybersecurity firm. With a presence in Canada and Pakistan, TISS delivers comprehensive cybersecurity solutions to organizations across the financial services, telecommunications, and public sectors. The firm’s team offers a broad suite of services, including security assessments, managed security operations, red team services, digital forensics & incident response, and GRC advisory. With nearly two decades of experience, TISS provides adaptive, intelligence-driven defenses that help clients anticipate and respond to evolving cyber threats. “At TISS, we work to create a safer digital environment by empowering organizations to operate securely and with confidence,” said Mahir Mohsin Sheikh, CEO of TISS. “Our collaboration with Andersen Consulting allows us to combine our deep technical expertise with a global consulting fr
I-Pulse Acquires CSI Technologies to Strengthen U.S. High-Energy Capacitor Manufacturing Capabilities18.3.2026 15:30:00 EET | Press release
Co-Founder, Chairman, and CEO, Robert Friedland, and Co-Founder and Chief Technology Officer, Laurent Frescaline, of I-Pulse, the world leader in high pulsed power technologies, are pleased to announce the acquisition of CSI Technologies, Inc., the California-based manufacturer of high-energy, high-voltage capacitors serving industrial, medical, and defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318099794/en/ The strategic acquisition enhances I-Pulse’s pulsed power development and U.S. manufacturing capabilities, particularly in mining, geothermal energy, mineral exploration, and water resource applications. By integrating CSI Technologies’ proven capacitor design and production expertise, I-Pulse strengthens its access to a reliable supply chain and expands its ability to rapidly design, prototype, and manufacture compact, high-energy-density capacitors. Co-Founder, Chairman, and CEO of I-Pulse Rob
Elliptic Integrates With Tempo, the Payments-First Blockchain18.3.2026 15:15:00 EET | Press release
Elliptic, the leader in digital asset decisioning, today announced full blockchain coverage for Tempo, the payments-first Layer-1 blockchain incubated by Stripe and Paradigm. With this integration, compliance and investigation teams gain full visibility into one of the most significant expansions of real-world financial activity onto blockchain infrastructure. "We're excited to have Elliptic providing compliance infrastructure on Tempo from day one. As payments move onchain at scale, builders and their customers need real-time tools to meet regulatory requirements without slowing down." – Nischay Upadhyayula, GTM, Tempo Tempo is a Layer-1 blockchain designed for real-world payments at scale, with sub-second finality and high throughput. Incubated by Stripe and Paradigm, Tempo is built for the transaction volumes that global commerce demands. Elliptic’s blockchain analytics platform is purpose-built to analyse on-chain data at this scale. “Tempo’s payment-specific blockchain infrastruct
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom